Clinical Research Division, Fred Hutch
Dr. Paul Carpenter is developing better treatments for graft-vs.-host disease. GVHD is a common complication of bone marrow transplantation that can cause serious illness and even death. In GVHD, donor immune cells attack the patient’s healthy cells. Dr. Carpenter leads clinical trials of new therapies for acute and chronic GVHD. He is studying new ways to overcome long-term complications of GVHD treatments and prevent relapse after transplant. Dr. Carpenter also cares for pediatric transplant patients and adults who are long-term survivors of transplantation.
Department of Pediatrics
University of Washington
Clinical Director Pediatric Blood and Marrow Transplant Program
Seattle Cancer Care Alliance
B.Sc., Medicine, University of Sydney, Australia
MB.BS., Medicine and Surgery, University of Sydney, Australia
Dr. Carpenter is participating in a multi-site trial that will collect and analyze samples from pediatric HCT patients in order to validate biomarkers of acute and chronic GVHD. Enrollment recently completed on a phase I/II clinical trial to determine if giving patients nilotinib 100 days after HCT is effective in reducing relapse in patients with Philadelphia chromosome-positive leukemias. Data analysis is beginning on a national multicenter trial he is leading that compared two chronic graft-versus-host disease drug regimens.
Study Number: 10032
Study Number: RG1003645
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.